Nkarta (NASDAQ:NKTX) Announces Earnings Results

Nkarta (NASDAQ:NKTX) issued its earnings results on Thursday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05), FiscalAI reports.

Nkarta Price Performance

Shares of NASDAQ NKTX traded up $0.16 during midday trading on Friday, hitting $1.73. 2,000,682 shares of the company’s stock were exchanged, compared to its average volume of 1,137,618. Nkarta has a twelve month low of $1.48 and a twelve month high of $3.72. The firm has a market cap of $123.90 million, a P/E ratio of -1.00 and a beta of 1.24. The stock’s 50 day moving average price is $2.34 and its 200-day moving average price is $2.51.

Analyst Upgrades and Downgrades

NKTX has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research report on Monday, September 21st. HC Wainwright assumed coverage on Nkarta in a research report on Monday, November 2nd. They issued a “buy” rating on the stock. Wall Street Zen cut Nkarta from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Stifel Nicolaus reduced their price target on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.20.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta’s research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.